The Drug Inside the Drug: How Medetomidine Is Breaking Every Overdose Response Playbook

On the morning the protocols failed, the patient presented the way staff at Jefferson Abington Hospital’s emergency department had seen hundreds of patients present before: unconscious, breathing shallow, brought in by a bystander who’d used naloxone twice at the scene. The naloxone had worked — in the narrow sense that the man began breathing again. But he didn’t wake up. He lay there, sedated, for hours, while clinicians worked through the checklist they use for prolonged post-naloxone sedation and found none of the expected answers. It wasn’t a brain injury. It wasn’t alcohol. It wasn’t a benzodiazepine on top of the opioids. He was just unconscious, in a way that Narcan didn’t fix, for reasons that didn’t fit the standard triage playbook.

What the patient had in his bloodstream was medetomidine.

“Patients are presenting to the [ED] with symptoms of withdrawal different from common opioid withdrawal symptoms,” Maria Foy, PharmD, an advanced clinical pharmacy specialist in pain management and opioid use disorder at Jefferson Abington, told Pharmacy Times this spring. “The ‘shaking’ people are experiencing is being misinterpreted as seizures.”

That sentence — the shaking is being misinterpreted as seizures — is a window into exactly how badly the clinical and public health infrastructure is scrambling to catch up with a drug that has quietly become the dominant adulterant in Philadelphia’s fentanyl supply, and is now detected in nine states across the eastern seaboard.

Xylazine’s replacement came fast

The pattern is almost identical to what happened with xylazine. Between 2019 and 2023, the veterinary tranquilizer crept into the street fentanyl supply in Philadelphia and then spread nationally, creating overdoses that Narcan couldn’t fully reverse, wounds that wouldn’t heal, and a withdrawal syndrome that looked nothing like standard opioid detox. The harm reduction field spent three years building infrastructure around xylazine: test strips, wound care protocols, clinical guidelines. It was hard. People died who didn’t have to.

Then the supply shifted again.

From May to November 2024, the percentage of Philadelphia’s drug checking samples containing medetomidine climbed from 29% to 87%. Over the same period, xylazine fell from 97% to 42%. The drugs didn’t leave the supply — they traded dominance. By the end of 2024, medetomidine was in over 70% of Philadelphia’s illicit fentanyl. By early 2026, it was confirmed in Florida, Indiana, Maryland, New Jersey, Ohio, Virginia, and Washington, D.C. The United States imported 813 medetomidine shipments in 2024, making it the largest global importer. The substance is a racemic mixture whose active isomer — dexmedetomidine, sold commercially as Precedex — is used in human ICUs for procedural sedation. In that clinical setting, it’s carefully titrated. On the street, there’s no titration.

Medetomidine is an alpha-2-adrenergic receptor agonist, the same drug class as xylazine, clonidine, and guanfacine. It produces sedation, analgesia, and muscle relaxation by inhibiting norepinephrine release in the central nervous system. But it is 200 times more potent than xylazine and 10 times more selective to the receptor subtype it targets. When you put 200x more potency into a drug supply that was already killing tens of thousands of people annually, and add it to fentanyl, a synthetic opioid already at near-saturation levels in the supply — things get complicated in ways the existing overdose response infrastructure wasn’t designed for.

Naloxone works. Then it doesn’t.

The core problem isn’t that naloxone stops working. It’s that naloxone only ever worked on one part of the problem.

When someone overdoses on fentanyl adulterated with medetomidine, naloxone does exactly what it’s supposed to do: it reverses the opioid-receptor-mediated respiratory depression. The person starts breathing again. But medetomidine doesn’t act on opioid receptors. It acts on alpha-2-adrenergic receptors, and naloxone has no activity at those receptors. So the naloxone reverses the fentanyl. The medetomidine remains. The person breathes — and stays profoundly sedated.

It acts on alpha-2-adrenergic receptors, and naloxone has no activity at those receptors.

In the hospital, there are veterinary reversal agents: atipamezole and yohimbine both reverse alpha-2-adrenergic agonists. Neither is FDA-approved for use in humans. Neither has been through the clinical trial pipeline required for that approval. Emergency physicians have limited options — supportive care, monitoring, waiting — while a patient lies in a hospital bed sedated by a drug for which no approved antidote exists for humans.

Outside the hospital, at the scene of an overdose, this presents as something deeply confusing to bystanders and first responders: a person who received naloxone and started breathing but didn’t regain consciousness. The standard bystander guidance — give Narcan, call 911, stay until they’re awake — doesn’t map onto this scenario in a satisfying way. The person needs 911. They need transport. They need monitoring they can only get in a clinical setting. But they’re breathing, and the bystander sees breathing and thinks the naloxone worked, and the complexity of what’s happening in that body may not be visible until the situation deteriorates.

Harm reduction programs in Philadelphia are now distributing medetomidine test strips to community-based organizations — an effort to at least give people using drugs the chance to know what’s in their supply. But test strips are a partial answer to a structural problem. They identify the presence of a substance; they don’t change what happens once it’s in someone’s body.

The withdrawal they’re not trained for

The acute overdose is one crisis. The withdrawal syndrome is another.

When xylazine entered the supply at scale, emergency physicians and addiction medicine specialists discovered that xylazine withdrawal — while not life-threatening on its own — complicated opioid withdrawal management in ways that required protocol updates. Xylazine didn’t produce a withdrawal syndrome that was independently fatal. Medetomidine’s does.

Quitting medetomidine cold-turkey is life-threatening. The withdrawal presents with severe tremors that staff in emergency departments are consistently misidentifying as seizures. It produces delirium — not a feature of standard opioid withdrawal — along with intractable nausea and vomiting, cardiovascular instability, and a clinical picture that shifts rapidly from apparent intoxication to acute withdrawal without the gradual progression experienced providers use to pace their interventions. In Philadelphia, where medetomidine hit first and hardest, 91% of hospitalized patients presenting with medetomidine withdrawal required ICU-level care. That is not a number that scales gracefully to a national addiction treatment system already running near capacity.

The existing opioid withdrawal protocols — the Clinical Opiate Withdrawal Scale, the standard buprenorphine induction procedures, the comfort medications that have been refined over decades of practice — were designed without medetomidine in the equation. As a published review in the Annals of Emergency Medicine put it in 2026, “existing protocols that effectively controlled withdrawal symptoms in the era when xylazine was common are no longer adequate in the era of medetomidine.” The protocols that worked last year need revision. The clinical training that most emergency medicine residents and addiction medicine fellows received didn’t include this substance. The harm reduction workers who know their community’s drug supply better than any physician are now managing a compound they’ve had less than two years to learn.

One advantage, and what it doesn’t solve

Medetomidine comes with one piece of genuinely better news compared to xylazine: the wounds. Xylazine injection is associated with severe, slow-healing necrotic skin ulcers that have become a signature crisis of the tranq era, requiring months of wound care and, in severe cases, amputation. Medetomidine, based on available data, has not been linked to the same wound complications. The injection risks are standard for intravenous drug use generally — infection, abscess, vein damage — but not the specific necrotic wound pattern that xylazine produces. For harm reduction workers who have spent years managing xylazine wounds, this is a real and meaningful difference.

The injection risks are standard for intravenous drug use generally — infection, abscess, vein damage — but not the specific necrotic wound pattern that xylazine produces.

But no wounds does not mean no risk. It means a different risk profile, one that is in some ways more acutely dangerous because it concentrates the danger in the overdose event itself — in the 15 minutes after naloxone is administered when the person is breathing but won’t wake up — and in the inpatient setting, where withdrawal can send a person into an ICU without warning.

The infrastructure problem

In May 2024, when Philadelphia first began detecting medetomidine in a meaningful percentage of its drug supply, the public health response moved as fast as it could. The Philadelphia Department of Public Health issued a Health Alert Network advisory in June 2025, updated it in June 2026. The Annals of Emergency Medicine published a clinical guidance paper earlier this year. Harm reduction organizations adapted their messaging and their test strip distribution.

That is, by any measure, a faster response than the field mounted to xylazine. But faster is not yet fast enough, because medetomidine is no longer a Philadelphia-specific problem. It is a nine-state problem, confirmed, and almost certainly present in more states where routine drug checking is limited or absent. Large sections of the country have no drug checking infrastructure at all — no fentanyl test strips distributed at scale, no point-of-care toxicology programs at harm reduction organizations, no systematic sample collection that would allow a health department to know what’s in the local supply before bodies start presenting at emergency rooms in ways that don’t make sense.

Medetomidine test strips exist. Getting them distributed requires funding, organizational capacity, and buy-in from programs already stretched by years of crisis-mode operation. In states where harm reduction is politically contested — where syringe service programs operate under legal ambiguity, where local officials have fought test strip distribution — the infrastructure for a rapid response to a new adulterant simply does not exist.

Rize tracks treatment facilities across the opioid crisis pillar and maintains updated service profiles including harm reduction offerings at facilities across Arizona. The picture on the ground is that many of the providers equipped to handle complex polysubstance presentations — the ones who would be first to see medetomidine-complicated withdrawal — are already running at capacity.

What comes after xylazine always comes

Maia Szalavitz, writing in Filter this past winter, framed the adulterant problem with the directness it deserves: the veterinary drug supply isn’t the problem. The problem is that the illicit drug market responds to law enforcement pressure by finding cheaper, more potent, more legally ambiguous compounds to add to its products, and the harm reduction and clinical infrastructure will always lag that market by years. Xylazine became a crisis because the policy response to fentanyl pushed the supply toward adulterants. Medetomidine is happening for the same reason.

The question isn’t whether there will be a next compound after medetomidine. There will be. The question is how long it will take for the clinical field to build evidence-based withdrawal protocols, for the harm reduction field to develop appropriate test strips and community-level guidance, and for the regulatory framework to make reversal agents available to the humans who need them — not just the animals they were approved for.

Right now, the answers to all three questions are: longer than the supply is going to wait.

Maria Foy put it plainly in her Pharmacy Times interview this spring, describing the patients arriving at Jefferson Abington’s emergency department with symptoms nobody trained for: “These are not the overdoses we were expecting.”

They rarely are. And that is, at this point, something the field should have built into its expectations — not as a counsel of despair, but as an argument for a surveillance system that doesn’t have to catch up to a crisis that’s already unfolding in ICU beds in nine states.

The patient who arrived at Jefferson Abington breathing but unconscious did eventually wake up. He was monitored for 18 hours, managed with supportive care, and discharged with harm reduction resources and a referral to outpatient treatment. Whether he made it into treatment isn’t part of the public record. What is on the record is that the staff who treated him had to improvise much of what they did, because the protocol for what was in his body didn’t exist yet.

He was monitored for 18 hours, managed with supportive care, and discharged with harm reduction resources and a referral to outpatient treatment.

That gap — between what’s in the supply and what the clinical and public health system knows how to do about it — is the story of the overdose crisis, told one new compound at a time.